185 related articles for article (PubMed ID: 26402387)
1. Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System.
Rashid N; Koh HA; Baca HC; Li Z; Malecha S; Abidoye O; Masaquel A
J Manag Care Spec Pharm; 2015 Oct; 21(10):863-71. PubMed ID: 26402387
[TBL] [Abstract][Full Text] [Related]
2. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system.
Rashid N; Koh HA; Baca HC; Lin KJ; Malecha SE; Masaquel A
Breast Cancer (Dove Med Press); 2016; 8():173-181. PubMed ID: 27785099
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
5. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
6. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. Factors responsible for long-term survival in metastatic breast cancer.
Kontani K; Hashimoto S; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Date M; Teramoto K; Houchi H; Yokomise H
World J Surg Oncol; 2014 Nov; 12():344. PubMed ID: 25395387
[TBL] [Abstract][Full Text] [Related]
10. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
[TBL] [Abstract][Full Text] [Related]
11. Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
Kehl KL; Niu J; Chavez-MacGregor M; Giordano SH
Cancer; 2018 Dec; 124(24):4685-4691. PubMed ID: 30264853
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
13. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
14. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
15. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment.
Schwenkglenks M; Jackisch C; Constenla M; Kerger JN; Paridaens R; Auerbach L; Bosly A; Pettengell R; Szucs TD; Leonard R
Support Care Cancer; 2006 Sep; 14(9):901-9. PubMed ID: 16622653
[TBL] [Abstract][Full Text] [Related]
16. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
17. A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.
Yamada H; Inoue K; Nagai SE; Nakai M; Arisawa F; Ueda H; Saito T; Ninomiya J; Kuroda T; Sakurai T; Kodama H; Kimizuka K; Hata S; Kai T; Kurosumi M;
J Nippon Med Sch; 2017; 84(5):215-223. PubMed ID: 29142182
[TBL] [Abstract][Full Text] [Related]
18. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
19. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
Ghate SR; Biskupiak J; Ye X; Kwong WJ; Brixner DI
J Manag Care Pharm; 2011 Nov; 17(9):672-84. PubMed ID: 22050392
[TBL] [Abstract][Full Text] [Related]
20. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]